title: Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
abstract: The impact of ribavirin exposure on virologic relapse remains controversial in combination therapy with pegylated interferon (Peg-IFN) and ribavirin for patients with chronic hepatitis C (CH-C) genotype 1. The present study was conducted to investigate this. Nine hundred and eighty-four patients with CH-C genotype 1 were enrolled. The drug exposure of each medication was calculated by averaging the dose actually taken. For the 472 patients who were HCV RNA negative at week 24 and week 48, multivariate logistic regression analysis showed that the degree of fibrosis (P = 0.002), the timing of HCV RNA negativiation (P < 0.001) and the mean doses of ribavirin (P < 0.001) were significantly associated with relapse, but those of Peg-IFN were not. Stepwise reduction of the ribavirin dose was associated with a stepwise increase in relapse rate from 11% to 60%. For patients with complete early virologic response (c-EVR) defined as HCV RNA negativity at week 12, only 4% relapse was found in patients given > or = 12 mg/kg/day of ribavirin and ribavirin exposure affected the relapse even after treatment week 12, while Peg-IFN could be reduced to 0.6 microg/kg/week after week 12 without the increase of relapse rate. Ribavirin showed dose-dependent correlation with the relapse. Maintaining as high a ribavirin dose as possible (> or = 12 mg/kg/day) during the full treatment period can lead to suppression of the relapse in HCV genotype 1 patients responding to Peg-IFN alpha-2b plus ribavirin, especially in c-EVR patients.
authors: Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan. hiramatsu@gh.med.osaka-u.ac.jp
authors: N
authors: N
authors: Hiramatsu
authors: T
authors: T
authors: Oze
authors: T
authors: T
authors: Yakushijin
authors: Y
authors: Y
authors: Inoue
authors: T
authors: T
authors: Igura
authors: K
authors: K
authors: Mochizuki
authors: K
authors: K
authors: Imanaka
authors: A
authors: A
authors: Kaneko
authors: M
authors: M
authors: Oshita
authors: H
authors: H
authors: Hagiwara
authors: E
authors: E
authors: Mita
authors: T
authors: T
authors: Nagase
authors: T
authors: T
authors: Ito
authors: Y
authors: Y
authors: Inui
authors: T
authors: T
authors: Hijioka
authors: K
authors: K
authors: Katayama
authors: S
authors: S
authors: Tamura
authors: H
authors: H
authors: Yoshihara
authors: Y
authors: Y
authors: Imai
authors: M
authors: M
authors: Kato
authors: Y
authors: Y
authors: Yoshida
authors: T
authors: T
authors: Tatsumi
authors: K
authors: K
authors: Ohkawa
authors: S
authors: S
authors: Kiso
authors: T
authors: T
authors: Kanto
authors: A
authors: A
authors: Kasahara
authors: T
authors: T
authors: Takehara
authors: N
authors: N
authors: Hayashi
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b